CT HB06870

Commissioner of Consumer Protection must hire a consultant to study feasibility of a Canadian prescription drug importation program by October 1, 2027, with potential FDA approval sought if deemed feasible

Starting January 1, 2026, pharmaceutical manufacturers and wholesale distributors are prohibited from selling certain off-patent brand-name drugs, generic drugs, and interchangeable biologics at prices exceeding their reference price adjusted for inflation

Violators of the price cap face civil penalties equal to 80% of excess revenue earned, applicable to those with at least $250,000 in annual Connecticut sales, with penalties collected by the Commissioner of Revenue Services

Manufacturers must provide 180 days advance notice to the Office of Health Strategy before withdrawing an identified prescription drug from sale in Connecticut, with $500,000 penalty for violations

Health insurers must credit patients' in-network deductibles and out-of-pocket maximums for prescription drugs purchased directly from pharmacies when the cash price is lower than the insurer's negotiated rate, effective January 1, 2026